

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/921,290
				Filing Date	August 3, 2001
				First Named Inventor	GOLDENBERG <i>et al.</i>
				Art Unit	1642 / 1643
Sheet	1	of	8	Examiner Name	Alana M. HARRIS
				Attorney Docket Number	40923-0079 US2 (18733-1012)


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ²	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
amb	1.	US-4,036,945	07-19-1977	Haber <i>et al.</i>	
	2.	US-4,331,647	05-25-1982	Goldenberg	
	3.	US-4,624,846	11-25-1986	Goldenberg	
	4.	US-4,824,659	04-25-1989	Hawthorne	
	5.	US-4,946,778	08-07-1990	Ladner <i>et al.</i>	
	6.	US-5,057,313	10-15-1991	Shih <i>et al.</i>	
	7.	US-5,120,525	06-09-1992	Goldenberg	
	8.	US-5,169,775	12-08-1992	Steplewski <i>et al.</i>	
	9.	US-5,443,953	08-22-1995	Hansen <i>et al.</i>	
	10.	US-5,484,892	01-16-1996	Tedder <i>et al.</i>	
	11.	US-5,686,072	11-11-1997	Uhr <i>et al.</i>	
amb	12.	US-5,789,544	08-04-1998	Miyamura <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² Number ³ Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
amb	1.	EP 510 949 A2	10-28-1992	Pouletty		
	2.	WO 91/11465	08-08-1991	Goldenberg <i>et al.</i>		
	3.	WO 95/09917	04-13-1995	Morrison <i>et al.</i>		
	4.	WO 96/04925	02-22-1996	Leung <i>et al.</i>		
	5.	WO 98/42378	10-01-1998	Goldenberg		
	6.	WO 99/02567	01-21-1999	Ghetie <i>et al.</i>		

Examiner Signature	<i>Alana Harris</i>	Date Considered	12 Jan 2007
--------------------	---------------------	-----------------	-------------

*Examiner: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Patent Information Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/921,290
				Filing Date	August 3, 2001
				First Named Inventor	GOLDENBERG <i>et al.</i>
				Art Unit	1642 / 1643
Sheet	2	of	8	Examiner Name	Alana M. HARRIS
				Attorney Docket Number	40923-0079 US2 (18733-1012)

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
Am Harris	1.	Aasted <i>et al.</i> , <i>Vet. Immunol. Immunopathol.</i> , 19:31 (1988).	
	2.	Adang <i>et al.</i> , <i>Plant Molec. Biol.</i> , 21:1131 (1993).	
	3.	Appelbaum <i>et al.</i> , <i>Hematol. Oncol.</i> , 2:151 (1984).	
	4.	Ausubel <i>et al.</i> , <i>Current Protocols in Molecular Biology</i> , pp. 8.2.8-8.2.13, John Wiley & Sons, New York (1990).	
	5.	Ausubel <i>et al.</i> , <i>Short Protocols in Molecular Biology</i> , 3rd Ed., pp. 8-8 to 8-9 (John Wiley & Sons, Inc., 1995).	
	6.	Baines <i>et al.</i> , <i>Methods in Molecular Biology</i> , Vol. 10, pp. 79-104 (The Humana Press, 1992).	
	7.	Baldwin <i>et al.</i> , "Immunotoxins in Cancer Treatment", <i>Biological Approaches to Cancer Treatment: Biomodulation</i> , pp. 252-276, Mitchell (Ed.), McGraw-Hill (1993).	
	8.	Bambot <i>et al.</i> , <i>PCR Methods and Applications</i> , 2:266 (1993).	
	9.	Batra <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 89:5867 (1992).	
	10.	Baum <i>et al.</i> , <i>Cancer</i> , 73 (Suppl. 3):896 (1994).	
	11.	Becker <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 93:7826 (1996).	
	12.	Behr <i>et al.</i> , <i>Clin. Cancer Res. Suppl.</i> 5 (Suppl 10):3304s (1999).	
	13.	Bird <i>et al.</i> , <i>Science</i> , 242:423 (1988).	
	14.	Boleti <i>et al.</i> , <i>Ann. Oncol.</i> , 6:945 (1995).	
	15.	Brinkmann <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 88:8616 (1991).	
	16.	Brunnert <i>et al.</i> , <i>J. Vet. Diagn. Invest.</i> , 3:245 (1991).	
	17.	Caniatti <i>et al.</i> , <i>Vet. Pathol.</i> , 33(2):204 (1996).	
	18.	Caron <i>et al.</i> , <i>Clin. Cancer Res.</i> , 4:1421 (1998).	
	19.	Carter <i>et al.</i> , <i>Canad. J. Vet. Res.</i> , 50:154 (1986).	
	20.	Carter <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 89:4285 (1992).	
	21.	Chase, "Medical Applications of Radioisotopes", <i>Remington's Pharmaceutical Sciences</i> , pp. 624-652, 18th Ed., Gennaro <i>et al.</i> (eds.) (Mack Publishing Co. 1990).	
	22.	Chaudhary <i>et al.</i> , <i>Nature</i> , 339:394 (1989).	
	23.	Cobbold <i>et al.</i> , <i>Tissue Antigens</i> , 43:137 (1994).	
	24.	Coligan <i>et al.</i> (eds.), <i>Current Protocols in Immunology</i> , Vol. 1, pp. 2.5.1-2.6.7; pp. 2.7.1-2.7.12; 2.8.1-2.8.10; 2.9.1-2.9.3; 2.10-2.10.4, John Wiley & Sons (1991).	

Examiner Signature	Am Harris	Date Considered	01/12/2007
--------------------	-----------	-----------------	------------

*Examiner: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. ¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	09/921,290
				Filing Date	August 3, 2001
				First Named Inventor	GOLDENBERG <i>et al.</i>
				Art Unit	1642 1643
				Examiner Name	Alana M. HARRIS
Sheet	3	of	8	Attorney Docket Number	40923-0079 US2 (18733-1012)

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	25.	Courtenay-Luck, "Genetic Manipulation of Monoclonal Antibodies", <i>Monoclonal Antibodies: Production, Engineering, and Clinical Application</i> , Cambridge University Press, pp. 166-179, Ritter <i>et al.</i> (eds.) (1995).	
	26.	Darbès <i>et al.</i> , <i>J. Vet. Diagn. Invest.</i> , 9:94 (1997).	
	27.	Day <i>et al.</i> , <i>J. Comp. Pathol.</i> , 120(2):155 (1999).	
	28.	Deonarain <i>et al.</i> , <i>Tumor Targeting</i> , 1:177 (1995).	
	29.	Dillman, <i>J. Clin. Oncol.</i> , 12(7):1497 (1994).	
	30.	Dillon <i>et al.</i> , "Use of the Polymerase Chain Reaction for the Rapid Construction of Synthetic Genes", <i>Methods in Molecular Biology</i> , Vol. 15, <i>PCR Protocols: Current Methods and Applications</i> , White (Ed.), pp. 263-268 (Humana Press, Inc. 1993).	
	31.	Dohlsten <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 91:8945 (1994).	
	32.	Edelman <i>et al.</i> , <i>Methods in Enzymology</i> , 1:422 (1967).	
	33.	Ellis <i>et al.</i> , <i>J. Immunol.</i> , 155:925 (1995).	
	34.	Flavell <i>et al.</i> , <i>Cancer Res.</i> , 57:4824 (1997).	
	35.	Fominaya <i>et al.</i> , <i>J. Biol. Chem.</i> , 271:10560 (1996).	
	36.	Foon <i>et al.</i> , <i>Annals Int. Medicine</i> , 113:525 (1990).	
	37.	Fournel-Fleury <i>et al.</i> , <i>J. Comp. Pathol.</i> , 117(1):35 (1997).	
	38.	Freedman <i>et al.</i> , <i>Hematol. Oncol. North Am.</i> , 4:405 (1990).	
	39.	Freedman <i>et al.</i> , "Non-Hodgkin's Lymphomas", <i>Cancer Medicine</i> , Vol. 2, 3rd ed., pp. 2028-2068, Holland <i>et al.</i> (eds.), Lea & Febiger (1993).	
	40.	Friedman <i>et al.</i> , <i>J. Immunol.</i> , 150:3054 (1993).	
	41.	French <i>et al.</i> , <i>Leukemia Res.</i> , 20(7):607 (1996).	
	42.	Galkowska <i>et al.</i> , <i>Vet. Immunol. Immunopathol.</i> , 53:329 (1996).	
	43.	Gennaro, <i>Remington's Pharmaceutical Sciences</i> , 19th Ed., Vol. I and II, Mack Publishing Co. (1995).	
	44.	Ghetie <i>et al.</i> , <i>Cancer Res.</i> , 48:2610 (1988).	
	45.	Goldenberg <i>et al.</i> , <i>J. Clin. Oncol.</i> , 9:548 (1991).	
	46.	Goldenberg, <i>CA-A Cancer J. for Clinicians</i> , 44(1):43 (1994).	
	47.	Goodman <i>et al.</i> , <i>Leukemia and Lymphoma</i> , 22:1 (1996).	
	48.	Goodman and Gilman's <i>The Pharmacological Basis of Therapeutics</i> , 7th Ed., MacMillan Publishing Co. (1985).	

Examiner Signature		Date Considered	12 Jan 2007
--------------------	--	-----------------	-------------

*Examiner: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. ¹ Applicant's unique citation designation number (optional). ⁴ Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449-PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	09/921,290
				Filing Date	August 3, 2001
				First Named Inventor	GOLDENBERG <i>et al.</i>
				Art Unit	1642 / 1643
				Examiner Name	Alana M. HARRIS
Sheet	4	of	8	Attorney Docket Number	40923-0079 US2 (18733-1012)

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
[Signature]	49.	Green <i>et al.</i> , <i>Nature Genet.</i> , 7:13 (1994).	
	50.	Greenlee <i>et al.</i> , <i>Vet. Immunol. Immunopathol.</i> , 15:285 (1987).	
	51.	Grindem, <i>Vet. Clin. N. Amer.</i> , 26:1043 (1996).	
	52.	Grossbard <i>et al.</i> , <i>Blood</i> , 80(4):863 (1992).	
	53.	Hank <i>et al.</i> , <i>Clin. Cancer Res.</i> , 2:1951 (1996).	
	54.	Hasan <i>et al.</i> , <i>Prog. Clin. Biol. Res.</i> , 288:471 (1989).	
	55.	Hekman <i>et al.</i> , <i>Cancer Immunol. Immunother.</i> , 32:364 (1991).	
	56.	Hu <i>et al.</i> , <i>Cancer Res.</i> , 56:4998 (1996).	
	57.	Inbar <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 69:2659 (1972).	
	58.	Jacobsen <i>et al.</i> , <i>Vet. Immunol. Immunopathol.</i> , 39:461 (1993).	
	59.	Jones <i>et al.</i> , <i>Nature</i> , 321:522 (1986).	
	60.	Jori <i>et al.</i> (Eds.), <i>Photodynamic Therapy of Tumors and Other Diseases</i> , Libreria Progetto (1985).	
	61.	Jurcic <i>et al.</i> , <i>Clin. Cancer Res.</i> , 6:372 (2000).	
	62.	Juweid <i>et al.</i> , <i>Cancer Res.</i> (suppl.), 55:5899s (1995).	
[Signature]	63.	Kaminski <i>et al.</i> , <i>New Eng. J. of Med.</i> , 329(7):459 (1993).	
	64.	Kiesel <i>et al.</i> , <i>Leukemia Res.</i> , 11(12):1119 (1987).	
	65.	Klegerman <i>et al.</i> , "Lymphokines and Monokines", <i>Biotechnology and Pharmacy</i> , pp. 53-70, Pessuto <i>et al.</i> (eds.), Chapman & Hall 1993).	
	66.	Köhler <i>et al.</i> , <i>Nature</i> , 256:495 (1975).	
	67.	Kreitman <i>et al.</i> , <i>Cancer Res.</i> , 53:819 (1993).	
	68.	Kreitman <i>et al.</i> , <i>Leukemia</i> , 7:553 (1993).	
	69.	Kuan <i>et al.</i> , <i>Biochemistry</i> , 35:2872 (1996).	
	70.	Ladiges <i>et al.</i> , <i>Am. J. Vet. Res.</i> , 49:870 (1988).	
	71.	Larrick <i>et al.</i> , <i>Methods: A Companion to Methods in Enzymology</i> , 2(2):106 (1991).	
	72.	Leung <i>et al.</i> , <i>Hybridoma</i> , 13:469 (1994).	
	73.	Leung <i>et al.</i> , <i>Mol. Immunol.</i> , 32(17/18):1413 (1995).	
	74.	Leung <i>et al.</i> , <i>J. Immunol.</i> , 154:5919 (1995).	


Examiner Signature	[Signature]	Date Considered	12 Jan 2007
--------------------	-------------	-----------------	-------------

*Examiner: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449, PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	09/921,290
				Filing Date	August 3, 2001
				First Named Inventor	GOLDENBERG <i>et al.</i>
				Art Unit	1642 <i>1643</i>
				Examiner Name	Alana M. HARRIS
Sheet	5	of	8	Attorney Docket Number	40923-0079 US2 (18733-1012)

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	75.	Li <i>et al.</i> , <i>Cell. Immunol.</i> , 118:85 (1989).	
	76.	Lienard <i>et al.</i> , <i>J. Clin. Oncol.</i> , 10:52 (1992).	
	77.	Linardou <i>et al.</i> , <i>Cell Biophys.</i> , 24-25:243 (1994).	
	78.	Lonberg <i>et al.</i> , <i>Nature</i> , 368:856 (1994).	
	79.	London <i>et al.</i> , <i>Exp. Hematol.</i> , 27:689 (1999).	
	80.	London <i>et al.</i> , <i>J. Comp. Pathol.</i> , 115:399 (1996).	
	81.	Longo, <i>Curr. Opin. Oncol.</i> , 8:353 (1996).	
	82.	Losman <i>et al.</i> , <i>Int. J. Cancer</i> , 46:310 (1990).	
	83.	Lundberg, <i>J. Pharm. Sci.</i> , 83(1):72 (1994).	
	84.	Lundberg <i>et al.</i> , <i>Int. J. Pharm.</i> , 134:119 (1996).	
	85.	MacEwen <i>et al.</i> , <i>J. Am. Vet. Med. Assoc.</i> , 178:1178 (1981).	
	86.	Maloney <i>et al.</i> , <i>Blood</i> , 84(8):2457 (1994).	
	87.	Mew <i>et al.</i> , <i>J. Immunol.</i> , 130:1473 (1983).	
	88.	Mew <i>et al.</i> , <i>Cancer Res.</i> , 45:4380 (1985).	
	89.	Mills <i>et al.</i> , <i>Proc. Am. Assoc. Cancer Res.</i> , 34:479 (abstract # 2857) (1993).	
	90.	Mole, "Epitope Mapping", <i>Methods in Molecular Biology, Vol. 10, Immunochemical Protocols</i> , pp. 105-116, Manson (ed.), The Humana Press (1992).	
	91.	Moore <i>et al.</i> , <i>Tissue Antigens</i> , 40:75 (1992).	
	92.	Murthy <i>et al.</i> , <i>Eur. J. Nucl. Med.</i> , 19:394 (1992).	
	93.	Nadeau <i>et al.</i> , <i>J. Pharmacol. Exp. Ther.</i> , 274:78 (1995).	
	94.	Nakaichi <i>et al.</i> , <i>J. Vet. Med. Sci.</i> , 58(5):469 (1996).	
	95.	Nicholls <i>et al.</i> , <i>J. Biol. Chem.</i> , 268:5302 (1993).	
	96.	Nicolet <i>et al.</i> , <i>Cancer Gene Ther.</i> , 2:161 (1995).	
	97.	Nisonoff <i>et al.</i> , <i>Arch. Biochem. Biophys.</i> , 89:230 (1960).	
	98.	Onizuka <i>et al.</i> , <i>Cancer Res.</i> , 59:3128 (1999).	
	99.	Ono <i>et al.</i> , <i>Mol. Immunol.</i> , 36:387 (1999).	
	100.	Orlandi <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 86:3833 (1989).	

Examiner Signature	<i>Alana Harris</i>	Date Considered	12 Jan 2007
--------------------	---------------------	-----------------	-------------

*Examiner: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. ¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449:PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	09/921,290
				Filing Date	August 3, 2001
				First Named Inventor	GOLDENBERG <i>et al.</i>
				Art Unit	1642 1643
				Examiner Name	Alana M. HARRIS
Sheet	6	of	8	Attorney Docket Number	40923-0079 US2 (18733-1012)

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
A	101.	Oseroff <i>et al.</i> , <i>Proc. Natl. Acad. Sci USA</i> , 83:8744 (1986).	
	102.	Oseroff <i>et al.</i> , <i>Photochem. Photobiol.</i> , 46:83 (1987).	
	103.	Ozaki <i>et al.</i> , <i>Blood</i> , 93:3922 (1999).	
	104.	Pack <i>et al.</i> , <i>Bio/Technology</i> , 11:1271 (1993).	
	105.	Pastan <i>et al.</i> , <i>Cell</i> , 47:641 (1986).	
	106.	Patti <i>et al.</i> , <i>Eur. J. Haematol.</i> , 51:18 (1993).	
	107.	Pawlak-Byczkowska <i>et al.</i> , <i>Cancer Res.</i> , 49:4568 (1989).	
	108.	Pèlegri <i>et al.</i> , <i>Cancer</i> , 67:2529 (1991).	
	109.	Porter <i>et al.</i> , <i>Biochem J.</i> , 73:119 (1959).	
	110.	Press <i>et al.</i> , <i>N. Eng. J. Med.</i> , 329(17):1219 (1993).	
V	111.	Press <i>et al.</i> , <i>The Lancet</i> , 346:336 (1995).	
	112.	Press, <i>Cancer Journal from Scientific American</i> , 4:S19 (1998).	
	113.	Price, "Production and Characterization of Synthetic Peptide-Derived Antibodies", <i>Monoclonal Antibodies: Production, Engineering, and Clinical Application</i> , Ritter <i>et al.</i> , (eds.), pp. 60-84, Cambridge University Press (1995).	
	114.	Reguera <i>et al.</i> , <i>Am. J. Dermatopathol.</i> , 22:49 (2000).	
	115.	Renner <i>et al.</i> , <i>Leukemia</i> , 11, supp. 2:S55 (1997).	
	116.	Riechmann <i>et al.</i> , <i>Nature</i> , 332:323 (1988).	
	117.	Ruslander <i>et al.</i> , <i>In Vivo</i> , 11(2):169 (1997).	
	118.	Saltzman <i>et al.</i> , <i>Biophys. J.</i> , 55:163 (1989).	
	119.	Sandhu, <i>Crit. Rev. Biotech.</i> , 12(5/6):437 (1992).	
	120.	Schechter <i>et al.</i> , <i>Arch. Biochem. Biophys.</i> , 262:232 (1988).	
V	121.	Schienvold <i>et al.</i> , <i>Transplantation</i> , 41:364 (1986).	
	122.	Schmidt <i>et al.</i> , <i>Int. J. Can.</i> , 65:538 (1996).	
	123.	Schwartz-Albiez <i>et al.</i> , "The Carbohydrate Moiety of the CD22 Antigen can be Modulated by Inhibitors of the Glycosylation Pathway", <i>Leukocyte Typing IV. White Cell Differentiation Antigens</i> , p. 65, Knapp <i>et al.</i> (eds.) (Oxford University Press, 1989).	
	124.	Shih <i>et al.</i> , <i>Int. J. Cancer</i> , 41:832 (1988).	

Examiner Signature	<i>Am Harris</i>	Date Considered	12 Jan 2007
--------------------	------------------	-----------------	-------------

*Examiner: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. ¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	09/921,290
				Filing Date	August 3, 2001
				First Named Inventor	GOLDENBERG <i>et al.</i>
				Art Unit	1642 1643
				Examiner Name	Alana M. HARRIS
Sheet	7	of	8	Attorney Docket Number	40923-0079 US2 (18733-1012)

NON-PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
dmm	125.	Shih <i>et al.</i> , <i>Int. J. Cancer</i> , 46:1101 (1990).		
	126.	Shih <i>et al.</i> , <i>Int. J. Cancer</i> , 56:538 (1994).		
	127.	Singer <i>et al.</i> , <i>J. Immun.</i> , 150:2844 (1993).		
	128.	Stein <i>et al.</i> , <i>Cancer Immunol. Immunother.</i> , 37(5):293 (1993).		
	129.	Stein <i>et al.</i> , <i>Antibody Immunoconj. Radiopharm.</i> , 4:703 (1991).		
	130.	Tatsuta <i>et al.</i> , <i>Lasers Surg. Med.</i> , 9:422 (1989).		
	131.	Taylor <i>et al.</i> , <i>Int. Immun.</i> , 6(4):579 (1994).		
	132.	Teske <i>et al.</i> , <i>Exper. Hematol.</i> , 22:1179 (1994).		
	133.	Thompson <i>et al.</i> , <i>J. Biol. Chem.</i> , 270:28037 (1995).		
	134.	Treon <i>et al.</i> , <i>Ann. Oncol.</i> , 11 (Suppl 1):107 (2000).		
	135.	Treon <i>et al.</i> , <i>Semin. Oncol.</i> , 26 (Suppl 14):97 (1999).		
	136.	Tsujimura <i>et al.</i> , <i>Leukemia</i> , 11 (Suppl 3):396 (1997).		
	137.	Upeslakis <i>et al.</i> , "Modification of Antibodies by Chemical Methods", <i>Monoclonal Antibodies: Principles and Applications</i> , pp. 187-230, Birch <i>et al.</i> (eds.) Wiley-Liss (1995).		
	138.	Vallera <i>et al.</i> , <i>Blood</i> , 88:2342 (1996).		
	139.	Van den Bergh, <i>Chem. Britain</i> , 22:430 (1986).		
	140.	Verhoeven <i>et al.</i> , <i>Science</i> , 239:1534 (1988).		
	141.	Vogelzang <i>et al.</i> , <i>J. Clin. Oncol.</i> , 11:1809 (1993).		
	142.	Vooijs <i>et al.</i> , <i>Cancer Immunol. Immunother.</i> , 42:319 (1996).		
143.	Vuist <i>et al.</i> , <i>Cancer Res.</i> , 49:3783 (1989).			
144.	Wang <i>et al.</i> , Abstracts of the 209th ACS National Meeting, Anaheim, CA, 2-6 April, 1995, Part 1, BIOT005.			
✓	145.	Ward <i>et al.</i> , "Genetic Manipulation and Expression of Antibodies", <i>Monoclonal Antibodies: Principles and Applications</i> , pp. 137-185, Birch <i>et al.</i> (eds.), Wiley-Liss, Inc. (1995).		
	146.	Weiss <i>et al.</i> , <i>J. Clin. Oncol.</i> , 10:275 (1992).		
	147.	Wels <i>et al.</i> , <i>Int. J. Can.</i> , 60:137 (1995).		
	148.	Whitlow <i>et al.</i> , <i>Methods: A Companion to Methods in Enzymology</i> , 2:97 (1991).		

Examiner Signature	<i>Alana M. Harris</i>	Date Considered	12 Jan 2007
--------------------	------------------------	-----------------	-------------

*Examiner: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. ¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449.PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	09/921,290
				Filing Date	August 3, 2001
				First Named Inventor	GOLDENBERG <i>et al.</i>
				Art Unit	1642 / 693
				Examiner Name	Alana M. HARRIS
Sheet	8	of	8	Attorney Docket Number	40923-0079 US2 (18733-1012)

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AMH	149.	Wilson <i>et al.</i> , <i>J. Exp. Med.</i> , 173:137 (1991).	
	150.	Wilson <i>et al.</i> , <i>J. Immunol.</i> , 150:5013 (1993).	
	151.	Wong, <i>Chemistry of Protein Conjugation and Cross-Linking</i> , CRC Press (1991).	
	152.	Wosnick <i>et al.</i> , <i>Gene</i> , 60:115 (1988).	
	153.	Yang <i>et al.</i> , <i>Hum. Antibodies Hybridomas</i> , 6:129 (1995).	
✓	154.	Yu <i>et al.</i> , <i>Int. J. Cancer</i> , 56:244 (1994).	
	155.	Copy of U.S. Provisional Patent Application Serial No. 60/223,698. 8 August 2000	
	156.		
	157.		
	158.		
	159.		
	160.		
	161.		
	162.		
	163.		
	164.		
	165.		
	166.		
	167.		
	168.		
	169.		
	170.		
	171.		
	172.		
	173.		
	174.		
	175.		
	176.		
	177.		
	178.		

Examiner Signature	AMHarris	Date Considered	12 Jan 2007
--------------------	----------	-----------------	-------------

* Examiner: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. ¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.